Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Liver Neoplasms × Axitinib × Clear all

Phase

Status

Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 19 Kidney Neoplasms 8 Neoplasms 7 Colorectal Neoplasms 5 Carcinoma 5 Carcinoma, Non-Small-Cell Lung 4 Carcinoma, Hepatocellular 4 Recurrence 3 Neoplasm Metastasis 3 Melanoma 3 Thyroid Neoplasms 2 Sarcoma 2 Lung Neoplasms 2 Kidney Diseases 2 Glioblastoma 2 Advanced Solid Tumors 2 cT2a N0NxM0 Renal Tumor 1 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solitary Fibrous Tumors 1 Solid Malignancies 1 Skin Neoplasms 1 Sarcoma, Alveolar Soft Part 1 Salivary Gland Neoplasms 1 Refractory or Recurrent Solid Tumors, Excluding CNS Tumors 1 Prostatic Neoplasms 1 Pheochromocytoma 1 Paraganglioma 1 Pancreatic Neoplasms 1

Interventions

Sorafenib 39 Bevacizumab 14 Oxaliplatin 13 Leucovorin 9 Fluorouracil 9 Doxorubicin 9 Radiofrequency Ablation 8 Hepatectomy 8 Gemcitabine 8 Cisplatin 8 Capecitabine 8 Radiosurgery 7 pembrolizumab 6 Nivolumab 6 Irinotecan 6 Drug Therapy 6 Cryosurgery 6 Carboplatin 6 Talaporfin 5 Mitomycin 5 spartalizumab 4 Melphalan 4 Everolimus 4 Erlotinib Hydrochloride 4 Embolization, Therapeutic 4 Electroporation 4 aldesleukin 3 Surveys and Questionnaires 3 Sunitinib 3 Sirolimus 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01334112 2019-12-12

AXITINIB

University Health Network, Toronto

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡